Medifast, Inc. (MED) Stock Competitors & Peer Comparison
See (MED) competitors and their performances in Stock Market.
Peer Comparison Table: Personal Products & Services Industry
Detailed financial metrics including price, market cap, P/E ratio, and more.
| Symbol | Price | Change % | Market Cap | P/E Ratio | EPS | Dividend Yield |
|---|---|---|---|---|---|---|
| MED | $12.18 | +0.91% | 135.4M | -6.69 | -$1.82 | N/A |
| ROL | $47.53 | +2.04% | 22.9B | 42.82 | $1.11 | +1.49% |
| SCI | $71.89 | +0.84% | 9.9B | 18.97 | $3.79 | +1.79% |
| HRB | $38.26 | +1.95% | 4.8B | 6.84 | $5.59 | +4.51% |
| FTDR | $65.87 | +3.72% | 4.6B | 18.82 | $3.50 | N/A |
| CVSA | $126.08 | -0.20% | 4.3B | 18.35 | $6.87 | N/A |
| BFAM | $61.51 | +3.94% | 3.2B | 18.53 | $3.32 | N/A |
| DSEY | $8.40 | +0.06% | 2.7B | -14.47 | -$0.58 | N/A |
| MCW | $7.10 | +0.00% | 2.3B | 21.52 | $0.33 | N/A |
| ROVR | $11.00 | +0.05% | 2B | 183.25 | $0.06 | N/A |
Stock Comparison
MED vs ROL Comparison June 2026
MED plays a significant role within the Consumer Cyclical sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MED stands at 135.4M. In comparison, ROL has a market cap of 22.9B. Regarding current trading prices, MED is priced at $12.18, while ROL trades at $47.53.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MED currently has a P/E ratio of -6.69, whereas ROL's P/E ratio is 42.82. In terms of profitability, MED's ROE is -0.10%, compared to ROL's ROE of +0.37%. Regarding short-term risk, MED is less volatile compared to ROL. This indicates potentially lower risk in terms of short-term price fluctuations for MED.Check ROL's competition here
MED vs SCI Comparison June 2026
MED plays a significant role within the Consumer Cyclical sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MED stands at 135.4M. In comparison, SCI has a market cap of 9.9B. Regarding current trading prices, MED is priced at $12.18, while SCI trades at $71.89.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MED currently has a P/E ratio of -6.69, whereas SCI's P/E ratio is 18.97. In terms of profitability, MED's ROE is -0.10%, compared to SCI's ROE of +0.39%. Regarding short-term risk, MED is more volatile compared to SCI. This indicates potentially higher risk in terms of short-term price fluctuations for MED.Check SCI's competition here
MED vs HRB Comparison June 2026
MED plays a significant role within the Consumer Cyclical sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MED stands at 135.4M. In comparison, HRB has a market cap of 4.8B. Regarding current trading prices, MED is priced at $12.18, while HRB trades at $38.26.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MED currently has a P/E ratio of -6.69, whereas HRB's P/E ratio is 6.84. In terms of profitability, MED's ROE is -0.10%, compared to HRB's ROE of -2.26%. Regarding short-term risk, MED is more volatile compared to HRB. This indicates potentially higher risk in terms of short-term price fluctuations for MED.Check HRB's competition here
MED vs FTDR Comparison June 2026
MED plays a significant role within the Consumer Cyclical sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MED stands at 135.4M. In comparison, FTDR has a market cap of 4.6B. Regarding current trading prices, MED is priced at $12.18, while FTDR trades at $65.87.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MED currently has a P/E ratio of -6.69, whereas FTDR's P/E ratio is 18.82. In terms of profitability, MED's ROE is -0.10%, compared to FTDR's ROE of +1.00%. Regarding short-term risk, MED and FTDR have similar daily volatility (3.30).Check FTDR's competition here
MED vs CVSA Comparison June 2026
MED plays a significant role within the Consumer Cyclical sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MED stands at 135.4M. In comparison, CVSA has a market cap of 4.3B. Regarding current trading prices, MED is priced at $12.18, while CVSA trades at $126.08.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MED currently has a P/E ratio of -6.69, whereas CVSA's P/E ratio is 18.35. In terms of profitability, MED's ROE is -0.10%, compared to CVSA's ROE of +0.17%. Regarding short-term risk, MED is more volatile compared to CVSA. This indicates potentially higher risk in terms of short-term price fluctuations for MED.Check CVSA's competition here
MED vs BFAM Comparison June 2026
MED plays a significant role within the Consumer Cyclical sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MED stands at 135.4M. In comparison, BFAM has a market cap of 3.2B. Regarding current trading prices, MED is priced at $12.18, while BFAM trades at $61.51.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MED currently has a P/E ratio of -6.69, whereas BFAM's P/E ratio is 18.53. In terms of profitability, MED's ROE is -0.10%, compared to BFAM's ROE of +0.14%. Regarding short-term risk, MED is less volatile compared to BFAM. This indicates potentially lower risk in terms of short-term price fluctuations for MED.Check BFAM's competition here
MED vs DSEY Comparison June 2026
MED plays a significant role within the Consumer Cyclical sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MED stands at 135.4M. In comparison, DSEY has a market cap of 2.7B. Regarding current trading prices, MED is priced at $12.18, while DSEY trades at $8.40.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MED currently has a P/E ratio of -6.69, whereas DSEY's P/E ratio is -14.47. In terms of profitability, MED's ROE is -0.10%, compared to DSEY's ROE of -0.23%. Regarding short-term risk, MED is more volatile compared to DSEY. This indicates potentially higher risk in terms of short-term price fluctuations for MED.Check DSEY's competition here
MED vs MCW Comparison June 2026
MED plays a significant role within the Consumer Cyclical sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MED stands at 135.4M. In comparison, MCW has a market cap of 2.3B. Regarding current trading prices, MED is priced at $12.18, while MCW trades at $7.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MED currently has a P/E ratio of -6.69, whereas MCW's P/E ratio is 21.52. In terms of profitability, MED's ROE is -0.10%, compared to MCW's ROE of +0.10%. Regarding short-term risk, MED is more volatile compared to MCW. This indicates potentially higher risk in terms of short-term price fluctuations for MED.Check MCW's competition here
MED vs ROVR Comparison June 2026
MED plays a significant role within the Consumer Cyclical sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MED stands at 135.4M. In comparison, ROVR has a market cap of 2B. Regarding current trading prices, MED is priced at $12.18, while ROVR trades at $11.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MED currently has a P/E ratio of -6.69, whereas ROVR's P/E ratio is 183.25. In terms of profitability, MED's ROE is -0.10%, compared to ROVR's ROE of -0.07%. Regarding short-term risk, MED is more volatile compared to ROVR. This indicates potentially higher risk in terms of short-term price fluctuations for MED.Check ROVR's competition here
MED vs CSV Comparison June 2026
MED plays a significant role within the Consumer Cyclical sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MED stands at 135.4M. In comparison, CSV has a market cap of 610.9M. Regarding current trading prices, MED is priced at $12.18, while CSV trades at $38.49.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MED currently has a P/E ratio of -6.69, whereas CSV's P/E ratio is 14.00. In terms of profitability, MED's ROE is -0.10%, compared to CSV's ROE of +0.18%. Regarding short-term risk, MED is more volatile compared to CSV. This indicates potentially higher risk in terms of short-term price fluctuations for MED.Check CSV's competition here
MED vs EM Comparison June 2026
MED plays a significant role within the Consumer Cyclical sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MED stands at 135.4M. In comparison, EM has a market cap of 303.1M. Regarding current trading prices, MED is priced at $12.18, while EM trades at $1.20.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MED currently has a P/E ratio of -6.69, whereas EM's P/E ratio is -119.50. In terms of profitability, MED's ROE is -0.10%, compared to EM's ROE of -0.01%. Regarding short-term risk, MED is more volatile compared to EM. This indicates potentially higher risk in terms of short-term price fluctuations for MED.Check EM's competition here
MED vs WW Comparison June 2026
MED plays a significant role within the Consumer Cyclical sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MED stands at 135.4M. In comparison, WW has a market cap of 180.1M. Regarding current trading prices, MED is priced at $12.18, while WW trades at $18.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MED currently has a P/E ratio of -6.69, whereas WW's P/E ratio is 1.63. In terms of profitability, MED's ROE is -0.10%, compared to WW's ROE of +3.34%. Regarding short-term risk, MED is less volatile compared to WW. This indicates potentially lower risk in terms of short-term price fluctuations for MED.Check WW's competition here
MED vs RGS Comparison June 2026
MED plays a significant role within the Consumer Cyclical sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MED stands at 135.4M. In comparison, RGS has a market cap of 67.4M. Regarding current trading prices, MED is priced at $12.18, while RGS trades at $26.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MED currently has a P/E ratio of -6.69, whereas RGS's P/E ratio is 0.60. In terms of profitability, MED's ROE is -0.10%, compared to RGS's ROE of +0.60%. Regarding short-term risk, MED is less volatile compared to RGS. This indicates potentially lower risk in terms of short-term price fluctuations for MED.Check RGS's competition here
MED vs XSPA Comparison June 2026
MED plays a significant role within the Consumer Cyclical sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MED stands at 135.4M. In comparison, XSPA has a market cap of 54.5M. Regarding current trading prices, MED is priced at $12.18, while XSPA trades at $0.66.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MED currently has a P/E ratio of -6.69, whereas XSPA's P/E ratio is 21.83. In terms of profitability, MED's ROE is -0.10%, compared to XSPA's ROE of +24.20%. Regarding short-term risk, MED is less volatile compared to XSPA. This indicates potentially lower risk in terms of short-term price fluctuations for MED.Check XSPA's competition here
MED vs EJH Comparison June 2026
MED plays a significant role within the Consumer Cyclical sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MED stands at 135.4M. In comparison, EJH has a market cap of 6.6M. Regarding current trading prices, MED is priced at $12.18, while EJH trades at $2.05.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MED currently has a P/E ratio of -6.69, whereas EJH's P/E ratio is N/A. In terms of profitability, MED's ROE is -0.10%, compared to EJH's ROE of +0.01%. Regarding short-term risk, MED is less volatile compared to EJH. This indicates potentially lower risk in terms of short-term price fluctuations for MED.Check EJH's competition here
MED vs XWEL Comparison June 2026
MED plays a significant role within the Consumer Cyclical sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MED stands at 135.4M. In comparison, XWEL has a market cap of 6.5M. Regarding current trading prices, MED is priced at $12.18, while XWEL trades at $1.07.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MED currently has a P/E ratio of -6.69, whereas XWEL's P/E ratio is -0.19. In terms of profitability, MED's ROE is -0.10%, compared to XWEL's ROE of +2.86%. Regarding short-term risk, MED is less volatile compared to XWEL. This indicates potentially lower risk in terms of short-term price fluctuations for MED.Check XWEL's competition here
MED vs MRM Comparison June 2026
MED plays a significant role within the Consumer Cyclical sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MED stands at 135.4M. In comparison, MRM has a market cap of 5.9M. Regarding current trading prices, MED is priced at $12.18, while MRM trades at $1.16.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MED currently has a P/E ratio of -6.69, whereas MRM's P/E ratio is 3.14. In terms of profitability, MED's ROE is -0.10%, compared to MRM's ROE of -0.68%. Regarding short-term risk, MED is less volatile compared to MRM. This indicates potentially lower risk in terms of short-term price fluctuations for MED.Check MRM's competition here
MED vs BYAH Comparison June 2026
MED plays a significant role within the Consumer Cyclical sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MED stands at 135.4M. In comparison, BYAH has a market cap of 1.1M. Regarding current trading prices, MED is priced at $12.18, while BYAH trades at $1.56.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MED currently has a P/E ratio of -6.69, whereas BYAH's P/E ratio is N/A. In terms of profitability, MED's ROE is -0.10%, compared to BYAH's ROE of -5.91%. Regarding short-term risk, MED is less volatile compared to BYAH. This indicates potentially lower risk in terms of short-term price fluctuations for MED.Check BYAH's competition here
MED vs TRNR Comparison June 2026
MED plays a significant role within the Consumer Cyclical sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MED stands at 135.4M. In comparison, TRNR has a market cap of 97K. Regarding current trading prices, MED is priced at $12.18, while TRNR trades at $0.70.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MED currently has a P/E ratio of -6.69, whereas TRNR's P/E ratio is -0.08. In terms of profitability, MED's ROE is -0.10%, compared to TRNR's ROE of -2.34%. Regarding short-term risk, MED is less volatile compared to TRNR. This indicates potentially lower risk in terms of short-term price fluctuations for MED.Check TRNR's competition here
MED vs IVP Comparison June 2026
MED plays a significant role within the Consumer Cyclical sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MED stands at 135.4M. In comparison, IVP has a market cap of 85.8K. Regarding current trading prices, MED is priced at $12.18, while IVP trades at $0.03.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MED currently has a P/E ratio of -6.69, whereas IVP's P/E ratio is -0.00. In terms of profitability, MED's ROE is -0.10%, compared to IVP's ROE of -5.20%. Regarding short-term risk, MED is more volatile compared to IVP. This indicates potentially higher risk in terms of short-term price fluctuations for MED.Check IVP's competition here
MED vs YYGH Comparison June 2026
MED plays a significant role within the Consumer Cyclical sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MED stands at 135.4M. In comparison, YYGH has a market cap of 2K. Regarding current trading prices, MED is priced at $12.18, while YYGH trades at $0.13.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MED currently has a P/E ratio of -6.69, whereas YYGH's P/E ratio is -0.01. In terms of profitability, MED's ROE is -0.10%, compared to YYGH's ROE of -1.36%. Regarding short-term risk, MED is less volatile compared to YYGH. This indicates potentially lower risk in terms of short-term price fluctuations for MED.Check YYGH's competition here
MED vs TMX Comparison June 2026
MED plays a significant role within the Consumer Cyclical sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MED stands at 135.4M. In comparison, TMX has a market cap of 0. Regarding current trading prices, MED is priced at $12.18, while TMX trades at $37.87.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MED currently has a P/E ratio of -6.69, whereas TMX's P/E ratio is 70.13. In terms of profitability, MED's ROE is -0.10%, compared to TMX's ROE of +0.05%. Regarding short-term risk, MED is less volatile compared to TMX. This indicates potentially lower risk in terms of short-term price fluctuations for MED.Check TMX's competition here
MED vs NEBCU Comparison June 2026
MED plays a significant role within the Consumer Cyclical sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MED stands at 135.4M. In comparison, NEBCU has a market cap of 0. Regarding current trading prices, MED is priced at $12.18, while NEBCU trades at $11.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MED currently has a P/E ratio of -6.69, whereas NEBCU's P/E ratio is N/A. In terms of profitability, MED's ROE is -0.10%, compared to NEBCU's ROE of -0.00%. Regarding short-term risk, MED is less volatile compared to NEBCU. This indicates potentially lower risk in terms of short-term price fluctuations for MED.Check NEBCU's competition here
MED vs STON Comparison June 2026
MED plays a significant role within the Consumer Cyclical sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MED stands at 135.4M. In comparison, STON has a market cap of 0. Regarding current trading prices, MED is priced at $12.18, while STON trades at $3.53.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MED currently has a P/E ratio of -6.69, whereas STON's P/E ratio is -6.64. In terms of profitability, MED's ROE is -0.10%, compared to STON's ROE of +0.48%. Regarding short-term risk, MED is more volatile compared to STON. This indicates potentially higher risk in terms of short-term price fluctuations for MED.Check STON's competition here